Hydrocarbon double-stapled stabilized HIV-1 GP41 heptad repeat domain peptides

Patent metadata

Field	Value
Publication number	US-10273290-B2
Application number	US-201715711058-A
Country	US
Kind code	B2
Filing date	Sep 21, 2017
Priority date	Jun 18, 2009
Publication date	Apr 30, 2019
Grant date	Apr 30, 2019

Abstract

The invention provides structurally constrained viral peptides for use as therapeutic and vaccination agents, and for the production of antibodies for use in a number of applications including as therapeutic agents. The invention further provides methods and kits for use of the structurally constrained peptides and antibodies of the instant invention. The invention is based, at least in part, on the result provided herein demonstrating the viral hydrocarbon stapled helical peptides display excellent proteolytic, acid, and thermal stability, restore the native helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.

First claim

What is claimed is:

1. A cross-linked polypeptide comprising a stabilized human immunodeficiency virus (HIV) gp41 heptad repeat (HR) domain, wherein the stabilized HIV gp41 HR domain is stabilized with two hydrocarbon staples, and wherein a hydrocarbon staple is positioned so as to link amino acid residues i and i+3, amino acid residues i and i+4, or amino acid residues i and i+7.

2. The cross-linked polypeptide of claim 1 , wherein one of the hydrocarbon staples is positioned so as to link amino acid residues i and i +3 relative to amino acid positions of a first helix of the polypeptide, and wherein one of said hydrocarbon staples is positioned so as to link amino acid residues i and i +4 relative to amino acid positions of a second helix of the polypeptide.

3. The cross-linked polypeptide of claim 1 , wherein a single face of a helix of the stabilized HIV gp41HR domain comprises one, two, three, or four adjacent stacked columns of amino acids, wherein the stacked column of amino acids is defined by positions a, d, and g; positions b and e; or positions c and f; in an alpha helix, wherein position a is an amino acid in the helix, and the amino acids are consecutively and serially assigned letters a through g in an alpha helix; or homologues thereof.

4. The cross-linked polypeptide of claim 1 , wherein the stabilized HIV gp41 HR domain comprises at least two amino acids on a single face of a helix of an HR-2 peptide, at least two interacting face amino acids of an HR-2 peptide, or a conservative substitution of an interacting face amino acid from SEQ ID NO: 1, wherein the interacting face amino acids of the HR-2 peptide are selected from the group consisting of amino acids corresponding to positions Thr-627, Trp-628, Trp-631, Asp-632, Arg-633, Ile-635, Tyr-638, Ile-642, Leu-645Ile-646, Ser-649, Gln-650, Gln-652, Gln-653, Glu-654, Lys-655, Asn-656, Glu-657, Glu-659, Leu-660, Glu-662, and Leu-663when numbered in accordance with SEQ ID NO: 1.

5. The cross-linked polypeptide of claim 4 , wherein the interacting face amino acids of the HR-2 peptide are selected from the group consisting of amino acids corresponding to positions Trp-628, Trp-631, Ile-635, Tyr-638, Ile-642, Leu-645, Ser-649, Gln-652, Asn-656, Glu-659, and Leu-663when numbered in accordance with SEQ ID NO: 1.

6. The cross-linked polypeptide of claim 1 , wherein the polypeptide is selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 26-40, SEQ ID NO: 45-48, SEQ ID NO: 58-63, and SEQ ID NO: 71-74.

7. The cross-linked polypeptide of claim 6 , wherein the carboxy-terminus of the cross-linked polypeptide is operably linked either directly or indirectly to the amino-terminus of an HIV gp41 membrane proximal external region (MPER) polypeptide selected from the group consisting of SEQ ID NO: 24, SEQ ID NO: 41-43, SEQ ID NO: 75-128; and SEQ ID NO: 135-140.

8. The cross-linked polypeptide of claim 1 , wherein the polypeptide is selected from the group consisting of SEQ ID NO: 17, SEQ ID NO: 49-57, and SEQ ID NO: 64-70.

9. The cross-linked polypeptide of claim 1 , wherein the stabilized HIV gp41HR domain comprises an amino acid mutation or a non-natural amino acid incorporation relative to amino acids 626-661of SEQ ID NO: 1.

10. The cross-linked polypeptide of claim 1 in a pharmaceutically acceptable carrier.

11. A kit comprising at least one cross-linked polypeptide of claim 1 and instructions for use.

12. The cross-linked polypeptide of claim 6 , wherein the polypeptide comprises:
SEQ ID NO: 27comprising a hydrocarbon staple between amino acid positions 4and 8;
SEQ ID NO: 46comprising a hydrocarbon staple between amino acid positions 28and 32;
SEQ ID NO: 47 comprising a hydrocarbon staple between amino acid positions 4 and 8;
SEQ ID NO: 48 comprising a hydrocarbon staple between amino acid positions 22 and 26;
SEQ ID NO: 71 comprising a hydrocarbon staple between amino acid positions 5and 9; and
SEQ ID NO: 72 comprising a hydrocarbon staple between amino acid positions 27and 31.

13. The cross-linked polypeptide of claim 6 , wherein the polypeptide comprises:
SEQ ID NO: 31 comprising a hydrocarbon staple between amino acid positions 4 and 8 and a hydrocarbon staple between amino acid positions 28and 32;
SEQ ID NO: 32 comprising a hydrocarbon staple between amino acid positions 5 and 9 and a hydrocarbon staple between amino acid positions 28 and 32;
SEQ ID NO: 33 comprising a hydrocarbon staple between amino acid positions 7 and 11 and a hydrocarbon staple between amino acid positions 28 and 32;
SEQ ID NO: 34 comprising a hydrocarbon staple between amino acid positions 15 and 19 and a hydrocarbon staple between amino acid positions 28 and 32;
SEQ ID NO: 35 comprising a hydrocarbon staple between amino acid positions 4 and 8 and a hydrocarbon staple between amino acid positions 27 and 31;
SEQ ID NO: 36 comprising a hydrocarbon staple between amino acid positions 5 and 9 and a hydrocarbon staple between amino acid positions 27 and 31;
SEQ ID NO: 37 comprising a hydrocarbon staple between amino acid positions 7 and 11 and a hydrocarbon staple between amino acid positions 27 and 31;
SEQ ID NO: 38 comprising a hydrocarbon staple between amino acid positions 15 and 19 and a hydrocarbon staple between amino acid positions 27 and 31;
SEQ ID NO: 39 comprising a hydrocarbon staple between amino acid positions 4 and 8 and a hydrocarbon staple between amino acid positions 15 and 19;
SEQ ID NO: 40 comprising a hydrocarbon staple between amino acid positions 5and 9 and a hydrocarbon staple between amino acid positions 15 and 19
SEQ ID NO: 58 comprising a hydrocarbon staple between amino acid positions 4and 8and a hydrocarbon staple between amino acid positions 28 and 32;
SEQ ID NO: 59 comprising a hydrocarbon staple between amino acid positions 7 and 11 and a hydrocarbon staple between amino acid positions 28 and 32;
SEQ ID NO: 60 comprising a hydrocarbon staple between amino acid positions 11 and 15 and a hydrocarbon staple between amino acid positions 28 and 32;
SEQ ID NO: 61 comprising a hydrocarbon staple between amino acid positions 15 and 19 and a hydrocarbon staple between amino acid positions 28 and 32;
SEQ ID NO: 62 comprising a hydrocarbon staple between amino acid positions 4 and 8 and a hydrocarbon staple between amino acid positions 22 and 26;
SEQ ID NO: 73 comprising a hydrocarbon staple between amino acid positions 5 and 9 and a hydrocarbon staple between amino acid positions 28 and 32; and
SEQ ID NO: 74 comprising a hydrocarbon staple between amino acid positions 5and 9 and a hydrocarbon staple between amino acid positions 27 and 31.

14. The cross-linked polypeptide of claim 6 , wherein the polypeptide comprises
SEQ ID NO: 63 comprising a hydrocarbon staple between amino acid positions 4 and 8, a hydrocarbon staple between amino acid positions 15 and 19, and a hydrocarbon staple between amino acid positions 28 and 32.

15. The cross-linked polypeptide of claim 7 , wherein the polypeptide comprises
SEQ ID NO: 41 comprising a hydrocarbon staple between amino acid positions 17 and 20;
SEQ ID NO: 42 comprising a hydrocarbon staple between amino acid positions 20 and 24;
SEQ ID NO: 43 comprising a hydrocarbon staple between amino acid positions 17 and 24;
SEQ ID NO: 75 comprising a hydrocarbon staple between amino acid positions 6 and 10;
SEQ ID NO: 76 comprising a hydrocarbon staple between amino acid positions 5and 9;
SEQ ID NO: 77 comprising a hydrocarbon staple between amino acid positions 4 and 8;
SEQ ID NO: 78 comprising a hydrocarbon staple between amino acid positions 3 and 7;
SEQ ID NO: 79 comprising a hydrocarbon

Assignees

• Dana Farber Cancer Inst Inc

Inventors

• Walensky Loren D
• Bird Gregory

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P31/18

  for HIV · CPC title

• A61P31/12

  Antivirals · CPC title

• A61K39/12

  Viral antigens · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title